Efficacy of Laser Acupuncture on Zanzhu (BL02) for Dry Age-related Macular Degeneration

February 15, 2024 updated by: Yu-Chen Lee, China Medical University Hospital

Efficacy of Laser Acupuncture on Zanzhu (BL02) as the Treatment for Dry Age-related Macular Degeneration: A Randomized Controlled Trial

This study is to see if laser acupuncture is a better way to treat dry-AMD (Age-related Macular Degeneration) compared to sham laser acupuncture, in the aspect of visual acuity. Investigators planed to recruit participants who are diagnosed with dry-AMD, and not younger than 20 years old. Before the study, investigators will measure the participants' BCVA (Best Corrected Visual Acuity), and then practice laser acupuncture and sham-laser acupuncture on experiment group and control group respectively. After the 4-week study, investigators will measure the participants' BCVA again.

Study Overview

Status

Enrolling by invitation

Detailed Description

This study consists of 15 visits, which are divided into the screening period and the treatment period.

Screening visit After being provided with sufficient information for this study, the patient would voluntarily sign the informed consent. The patients who have submitted the informed consent will undergo screening tests to determine their eligibility. The screening tests include general medical history taking, treatment history for AMD, vision test. Based on the eligibility criteria and screening tests, identification codes would be granted to eligible participants.

Visit 1 Visit 1 will be arranged within a week from the screening visit. The participants who have successfully completed the screening visit can proceed to visit 1 on the same day. The participant's changes in medical history and medication taking since the screening visit will be surveyed. Randomization will be performed on the eligible participants. Before implementing each intervention, examinations would be conducted to measure outcomes, BCVA. The participants would be educated according to the assigned intervention. The experimental group would receive laser acupuncture treatment, and the control group would receive the sham laser acupuncture. In both group, any discomfort or adverse events (AEs) before and after the treatment would be surveyed. Some observation items, including vital signs, vision test, medical history, medication taking, participant's compliance, discomfort before and after the treatment and AEs, will be examined every visit. Participant teaching would also be conducted during every visit.

Visits 2-12 During visits 2-12, the observation items will be examined including visual acuity, medical history, medication taking, discomfort before and after the treatment and AEs since the last visit. Both group would visit three times a week for 4 weeks. At each visit, the experimental group would receive the laser acupuncture treatment, and the control group would receive the sham laser acupuncture. In both group, discomfort before and after the treatment would be surveyed.

Visit 13 Visit 13 will be arranged within 3 days, after a 4-week period has elapsed since visit 1. (If 4 hours have elapsed since the treatment of visit 12, visit 13 could be arranged on the same day as visit 12.) For both group, a survey would be conducted to check any changes related to medical history, medication taking and AEs since visit 12. Vision test will be conducted. When the assessments have finished, treatment satisfaction will be evaluated.

Visit 14 Visit 14 will be arranged within 3 days, after a 6-week period has elapsed since visit 1. Any changes in medical history, medication taking and AEs since visit 13 will be surveyed. Final assessments for vision test will be conducted. Lastly, the participants' final compliance will be investigated.

Additional visits Additional visits can be arranged on the participants' request or if the investigators deem them necessary. Additional follow-ups for the appeared AEs could also be arranged. They would be permitted if the AEs continue until the trial is fully completed or stopped early, or if the investigators or the participants request additional follow-ups after finishing the treatment.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taichung, Taiwan, 404
        • China Medical University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Those who have been diagnosed with dry-AMD
  2. Male or female patients above 20 years of age at the screening visit
  3. Those who voluntarily signed the informed consent

Exclusion Criteria:

  1. Those who refuse to sign the consent form
  2. Pregnant women
  3. Individuals with epilepsy
  4. Patients with angina
  5. Individuals with hyperthyroidism
  6. Patients with a cardiac pacemaker
  7. Those who applied immunosuppressive agents containing Arsenic

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: laser acupuncture group
3 minutes for each time, and 3 times per week, with duration of 4 weeks
wavelength: 808nm energy: 18j power: 100mw
Sham Comparator: sham laser acupuncture group
3 minutes for each time, and 3 times per week, with duration of 4 weeks
wavelength: 0nm energy: 0j power: 0mw

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
BCVA (Best Corrected Visual Acuity)
Time Frame: "baseline (pre-intervention)", and "immediately after the intervention"
BCVA is the best possible vision an eye can see with corrective lenses. The gold standard for measuring BCVA is with the Early Treatment Diabetic Retinopathy (ETDRS) chart. The ETDRS score is calculated as the total number of letters correctly read at 4m from the chart plus 30 (if 20 or more letters can be read at 4m). If fewer than 20 letters can be read at 4m, the patient's position is adjusted to 1m in front of the chart.
"baseline (pre-intervention)", and "immediately after the intervention"

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Yu-Chen Lee, M.D. & Ph.D., China Medical University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 26, 2024

Primary Completion (Estimated)

November 1, 2024

Study Completion (Estimated)

November 1, 2024

Study Registration Dates

First Submitted

February 6, 2024

First Submitted That Met QC Criteria

February 15, 2024

First Posted (Actual)

February 20, 2024

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 15, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Age-related Macular Degeneration

Clinical Trials on laser acupuncture

Subscribe